Aug. 28, 2023
A potential best-in-class TRβ agonist prodrug for NASH demonstrates impressive efficacy and safety
VK2809
Liver targeted Thyroid Receptor β agonist prodrug Phase 2b NASH Analog of endogenous T3 Clinical data release, May 16, 2023 Viking Therapeutics
Loading...
